{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:11:29Z","timestamp":1793902289435,"version":"4.8.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:00:00Z","timestamp":1694217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:00:00Z","timestamp":1694217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11864-023-01117-9","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T03:01:21Z","timestamp":1694228481000},"page":"1367-1377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Opioid-induced Neurotoxicity in Patients with Cancer Pain"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9859-6487","authenticated-orcid":false,"given":"Sebastiano","family":"Mercadante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,9]]},"reference":[{"key":"1117_CR1","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40265-022-01780-6","volume":"82","author":"S Mercadante","year":"2022","unstructured":"\u2022 Mercadante S. Cancer Pain treatment strategies in patients with cancer. Drugs. 2022;82:1357\u201366. This reference is of importante because is a comprehensive review of strategies for cancer pain management.","journal-title":"Drugs"},{"key":"1117_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1034\/j.1399-6576.1999.430910.x","volume":"43","author":"PJ Daeninck","year":"1999","unstructured":"Daeninck PJ, Bruera E. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand. 1999;43:924\u201338.","journal-title":"Acta Anaesthesiol Scand"},{"key":"1117_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1526-5900(03)00556-X","volume":"4","author":"E McNicol","year":"2003","unstructured":"McNicol E, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231\u201356.","journal-title":"J Pain"},{"key":"1117_CR4","unstructured":"Bruera E, Pereira J. Neuropsychiatric toxicity of opioids. In: Jensen TS, Turner JA, Wiesenfeld-Hallen Z, eds. Proceedings of the 8th World Congress on Pain, Progress in Pain Re- search and Management, vol 8. Seattle: IASP Press, 1997: 717\u201338."},{"key":"1117_CR5","doi-asserted-by":"crossref","unstructured":"Pereira J, Bruera E. Emerging neuropsychiatric toxicities of opioids. In: AG Lipman, ed. Journal of Pharmaceutical Care in Pain and Symptom Control \u2013 Innovations in Drug Development, Evaluation and Use. New York: The Haworth Press Inc., 1997: 5: 3\u201329","DOI":"10.1300\/J088v05n04_02"},{"key":"1117_CR6","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.3390\/cancers13235893","volume":"13","author":"P Bramati","year":"2021","unstructured":"\u2022\u2022 Bramati P. Bruera E Delirium in palliative care. Cancers (Basel). 2021;13:5893. This reference is of outstanding importance because clearly explains the characteristics of many conditions of neurotoxicity.","journal-title":"Cancers (Basel)."},{"key":"1117_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0304-3959(97)00090-0","volume":"74","author":"S Mercadante","year":"1998","unstructured":"Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain. 1998;74:5\u20139.","journal-title":"Pain"},{"key":"1117_CR8","doi-asserted-by":"publisher","first-page":"8312","DOI":"10.1523\/JNEUROSCI.22-18-08312.2002","volume":"22","author":"J Mao","year":"2002","unstructured":"Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces down regulation of spinal glutamate transporters: implications in morphine intolerance and abnormal pain sensitivity. J Neurosci. 2002;22:8312\u201323.","journal-title":"J Neurosci"},{"issue":"3","key":"1117_CR9","first-page":"426","volume":"53","author":"R Gallagher","year":"2007","unstructured":"Gallagher R. Opioid-induced neurotoxicity. Can Fam Physician. 2007;53(3):426\u20137.","journal-title":"Can Fam Physician"},{"key":"1117_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0304-3959(96)03238-1","volume":"69","author":"E Bruera","year":"1997","unstructured":"Bruera E, Pereira J. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain. 1997;69:199\u2013201.","journal-title":"Pain"},{"key":"1117_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0196-0644(96)70205-6","volume":"27","author":"JC Adair","year":"1996","unstructured":"Adair JC, el-Nachef A, Cutler P. Fentanyl neurotoxicity. Ann Emerg Med. 1996;27:791\u20132.","journal-title":"Ann Emerg Med"},{"key":"1117_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0885-3924(02)00531-6","volume":"25","author":"G Andersen","year":"2003","unstructured":"Andersen G, Christrup L, Sjogren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain Symptom Manage. 2003;25:74\u20139.","journal-title":"J Pain Symptom Manage"},{"key":"1117_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1191\/0269216303pm658oa","volume":"17","author":"C Quigley","year":"2003","unstructured":"Quigley C, Joel S, Patel N, Baksh A, Slevin M. Plasma concentrations of morphine, morphine- 6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med. 2003;17:185\u201390.","journal-title":"Palliat Med"},{"key":"1117_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/104990910502200411","volume":"22","author":"S Mercadante","year":"2005","unstructured":"Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Care. 2005;22:291\u20134.","journal-title":"Am J Hosp Palliat Care"},{"key":"1117_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/15563650600981194","volume":"45","author":"H Karunatilake","year":"2007","unstructured":"Karunatilake H, Buckley NA. Severe neurotoxicity following oral meperidine (pethidine) overdose. Clin Toxicol (Phila). 2007;45:200\u20131.","journal-title":"Clin Toxicol (Phila)"},{"key":"1117_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/J354v21n01_05","volume":"21","author":"J Vella-Brincat","year":"2007","unstructured":"Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. J Pain Palliat Care Pharmacother. 2007;21:15\u201325.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"1117_CR17","doi-asserted-by":"publisher","first-page":"8312","DOI":"10.1523\/JNEUROSCI.22-18-08312.2002","volume":"22","author":"J Mao","year":"2002","unstructured":"Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces down regulation of spinal glutamate transporters: implications in morphine intolerance and abnormal pain sensitivity. J Neurosci. 2002;22:8312\u201323.","journal-title":"J Neurosci"},{"key":"1117_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40263-019-00660-0","volume":"33","author":"S Mercadante","year":"2019","unstructured":"Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs. 2019;33:943\u201355.","journal-title":"CNS Drugs"},{"key":"1117_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1213\/00000539-199901000-00021","volume":"88","author":"MT Smith","year":"1999","unstructured":"Smith MT, Wright AWE, Williams BE, Stuart G, Cramond T. Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management. Anesth Analg. 1999;88:109\u201316.","journal-title":"Anesth Analg"},{"key":"1117_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/0024-3205(90)90619-3","volume":"47","author":"MT Smith","year":"1990","unstructured":"Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci. 1990;47:579\u201385.","journal-title":"Life Sci"},{"key":"1117_CR21","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jpainsymman.2005.01.004","volume":"29","author":"J Lotsch","year":"2005","unstructured":"Lotsch J. Opioid metabolites. J Pain Symptom Manage. 2005;29:S10\u201324.","journal-title":"J Pain Symptom Manage"},{"key":"1117_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1191\/026921699678158579","volume":"13","author":"S Mercadante","year":"1999","unstructured":"Mercadante S. The role of morphine glucuronides in cancer pain. Palliat Med. 1999;13:95\u2013104.","journal-title":"Palliat Med"},{"key":"1117_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejphar.2015.10.049","volume":"769","author":"S Mercadante","year":"2015","unstructured":"Mercadante S. Opioid metabolism and clinical aspects. Eur J Pharmacol. 2015;769:71\u20138.","journal-title":"Eur J Pharmacol"},{"key":"1117_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/jpm.2004.7.545","volume":"7","author":"D Thwaites","year":"2004","unstructured":"Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. J Palliat Med. 2004;7:545\u201350.","journal-title":"J Palliat Med"},{"key":"1117_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1089\/jpm.2011.0502","volume":"16","author":"KM Juba","year":"2013","unstructured":"Juba KM, Wjaler RG, Daron SM. Morphine and hydromorphone-induced hyperalgesia in a hospice patient. J Palliat Med. 2013;16:809\u201312.","journal-title":"J Palliat Med"},{"key":"1117_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0304-3959(92)90065-J","volume":"48","author":"QL Gong","year":"1992","unstructured":"Gong QL, Hedner J, Bj\u00f6rkman R, et al. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain. 1992;48:249\u201355.","journal-title":"Pain"},{"key":"1117_CR27","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/jps.1131","volume":"90","author":"RT Penson","year":"2001","unstructured":"Penson RT, Joel SP, Clark S, et al. Limited phase I study of morphine-3-glucuronide. J Pharm Sci. 2001;90:1810\u20136.","journal-title":"J Pharm Sci"},{"key":"1117_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/01616412.2000.11740748","volume":"22","author":"WA Kofke","year":"2000","unstructured":"Kofke WA, Garman RH, Garman R, Rose M. Opioid neurotoxicity: role of neurotransmitter systems. Neurol Res. 2000;22:733\u20137.","journal-title":"Neurol Res"},{"key":"1117_CR29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1213\/00000539-199612000-00029","volume":"83","author":"WA Kofke","year":"1996","unstructured":"Kofke WA, Garman RH, Garman R, Stiller R, Rose ME. Opioid neurotoxicity: fentanyl dose-response effects in rats. Anesth Analg. 1996;83:1298\u2013306.","journal-title":"Anesth Analg"},{"key":"1117_CR30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3181\/00379727-87-21461","volume":"87","author":"JA Schneider","year":"1994","unstructured":"Schneider JA. Reserpine antagonism of morphine analgesia in mice. Proc Soc Exp Biol Med. 1994;87:614\u20135.","journal-title":"Proc Soc Exp Biol Med"},{"key":"1117_CR31","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00000542-198505000-00009","volume":"62","author":"I Kissin","year":"1985","unstructured":"Kissin I, Brown PT. Reserpine-induced changes in anesthetic action of fentanyl. Anesthesiology. 1985;62:597\u2013600.","journal-title":"Anesthesiology"},{"key":"1117_CR32","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0885-3924(03)00258-6","volume":"26","author":"S Mercadante","year":"2003","unstructured":"Mercadante S, Ferrera P, Villari P, et al. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage. 2003;26:769\u201375.","journal-title":"J Pain Symptom Manage"},{"key":"1117_CR33","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1634\/theoncologist.2015-0115","volume":"20","author":"M de la Cruz","year":"2015","unstructured":"de la Cruz M, Ransing V, Yennu S, et al. The frequency, characteristics, and outcomes among cancer patients with delirium admitted to an acute palliative care unit. Oncologist. 2015;20:1425\u201331.","journal-title":"Oncologist"},{"key":"1117_CR34","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/archinte.160.6.786","volume":"160","author":"PG Lawlor","year":"2000","unstructured":"Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160:786\u201394.","journal-title":"Arch Intern Med"},{"key":"1117_CR35","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1634\/theoncologist.2012-0269","volume":"18","author":"A Reddy","year":"2013","unstructured":"Reddy A, Yennurajalingam S, Pulivarthi K, et al. Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist. 2013;18:2212\u201320.","journal-title":"Oncologist"},{"key":"1117_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109260","volume":"220","author":"SY Lim","year":"2022","unstructured":"Lim SY, Cengiz P. Opioid tolerance and opioid-induced hyperalgesia: is TrkB modulation a potential pharmacological solution? Neuropharmacology. 2022;220: 109260.","journal-title":"Neuropharmacology"},{"key":"1117_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/0304-3959(93)90232-E","volume":"53","author":"N MacDonald","year":"1993","unstructured":"MacDonald N, Der L, Allan S, et al. Opioid hyperexcitability: the application of alternate opioid therapy. Pain. 1993;53:353\u20135.","journal-title":"Pain"},{"key":"1117_CR38","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1089\/jpm.2018.0169","volume":"21","author":"KH Lim","year":"2018","unstructured":"Lim KH, Nguyen NN, Qian Y, et al. Frequency, outcomes, and associated factors for opioid-induced neurotoxicity in patients with advanced cancer receiving opioids in inpatient palliative care. J Palliat Med. 2018;21:1698\u2013704.","journal-title":"J Palliat Med"},{"key":"1117_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1191\/026921601674921626","volume":"15","author":"A Fountain","year":"2001","unstructured":"Fountain A. Visual hallucinations: a prevalence study among hospice inpatients. Palliat Med. 2001;15:19\u201325.","journal-title":"Palliat Med"},{"key":"1117_CR40","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s00520-015-2610-3","volume":"23","author":"M De La Cruz","year":"2015","unstructured":"De La Cruz M, Fan J, Yennu S, et al. The frequency of missed delirium in patients referred to palliative care in a comprehensive cancer center. Support Care Cancer. 2015;23:2427\u201333.","journal-title":"Support Care Cancer"},{"key":"1117_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1176\/appi.psy.43.3.183","volume":"43","author":"W Breitbart","year":"2002","unstructured":"Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses\/caregivers, and their nurses. Psychosomatics. 2002;43:183\u201394.","journal-title":"Psychosomatics"},{"key":"1117_CR42","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/00000542-200603000-00025","volume":"104","author":"MS Angst","year":"2006","unstructured":"Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570\u201387.","journal-title":"Anesthesiology"},{"key":"1117_CR43","first-page":"141","volume":"14","author":"M Lee","year":"2011","unstructured":"Lee M, Silverman S, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Phys. 2011;14:141\u201361.","journal-title":"Pain Phys"},{"key":"1117_CR44","first-page":"419","volume":"104","author":"WE Ackerman 3rd","year":"2006","unstructured":"Ackerman WE 3rd. Paroxysmal opioid-induced pain and hyperalgesia. J Ky Med Assoc. 2006;104:419\u201323.","journal-title":"J Ky Med Assoc"},{"key":"1117_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11916-010-0171-1","volume":"15","author":"DA Tompkins","year":"2011","unstructured":"Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep. 2011;15:129\u201336.","journal-title":"Curr Pain Headache Rep"},{"key":"1117_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0269216307086857","volume":"22","author":"M Fallon","year":"2008","unstructured":"Fallon M, Colvin L. Opioid-induced hyperalgesia: fact or fiction? Palliat Med. 2008;22:5\u20136.","journal-title":"Palliat Med"},{"key":"1117_CR47","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/j.bja.2018.09.019","volume":"122","author":"C Higgins","year":"2019","unstructured":"\u2022\u2022 Higgins C, Smith BH, Matthews K. Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. Br J Anaesth. 2019;122:e114-26. This paper is of importance as analitically shows the evidence og opioid-induced hyperalgesia after chronic opioid exposure.","journal-title":"Br J Anaesth"},{"key":"1117_CR48","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2007.15.6919","volume":"26","author":"Z Zylicz","year":"2008","unstructured":"Zylicz Z, Twycross R. Opioid-induced hyperalgesia may be more frequent than previously thought. JCO. 2008;26:1564.","journal-title":"JCO"},{"key":"1117_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11916-010-0171-1","volume":"15","author":"DA Tompkins","year":"2011","unstructured":"Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep. 2011;15:129\u201336.","journal-title":"Curr Pain Headache Rep"},{"key":"1117_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006016","volume":"4","author":"KB Jensen","year":"2009","unstructured":"Jensen KB, Lonsdorf TB, Schalling M, Kosek E, Ingvar M. Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT val158met Polymorphism. PLoS ONE. 2009;4: e6016.","journal-title":"PLoS ONE"},{"key":"1117_CR51","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/01.fpc.0000236321.94271.f8","volume":"16","author":"DY Liang","year":"2006","unstructured":"Liang DY, Liao G, Lighthall GK, Peltz G, Clark DJ. Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence. Pharmacogenet Genom. 2006;16:825\u201335.","journal-title":"Pharmacogenet Genom"},{"issue":"8","key":"1117_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135711","volume":"10","author":"FA Oladosu","year":"2015","unstructured":"Oladosu FA, Conrad MC, O\u2019Buckley SC, Rashid NU, Slade DG, Nackley AG. Mu opioid splice variant MOR-1K contributes to the development of opioid-induced hyperalgesia. PLoS ONE. 2015;10(8): e0135711.","journal-title":"PLoS ONE"},{"key":"1117_CR53","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0025-6196(11)63006-1","volume":"71","author":"JN Caviness","year":"1996","unstructured":"Caviness JN. Myoclonus. Mayo Clin Proc. 1996;71:679\u201388.","journal-title":"Mayo Clin Proc"},{"key":"1117_CR54","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/106002809603000517","volume":"30","author":"TM Brown","year":"1996","unstructured":"Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother. 1996;30:527\u201333.","journal-title":"Ann Pharmacother"},{"key":"1117_CR55","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF01271247","volume":"103","author":"J Staedt","year":"1996","unstructured":"Staedt J, Stoppe G, Riemann H, Hajak G, Ruther E, Riederer P. Lamotrigine in the treatment of nocturnal myoclonus syndrome. Two case reports. J Neural Transm. 1996;103:355\u201361.","journal-title":"J Neural Transm"},{"key":"1117_CR56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/01.NAJ.0000435351.53534.83","volume":"113","author":"M Matzo","year":"2013","unstructured":"Matzo M, Dawson KA. Opioid-induced neurotoxicity. Am J Nurs. 2013;113:51\u20136.","journal-title":"Am J Nurs"},{"key":"1117_CR57","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1089\/jpm.2008.9874","volume":"116","author":"DK Bower","year":"2008","unstructured":"Bower DK. Opioid-induced neurotoxicity: too much of a good thing. J Palliat Med. 2008;116:947\u20138.","journal-title":"J Palliat Med"},{"key":"1117_CR58","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jpain.2003.09.007","volume":"5","author":"S Mercadante","year":"2004","unstructured":"Mercadante S, Arcuri E. Opioids and rena function. J Pain. 2004;5:2\u201319.","journal-title":"J Pain"},{"key":"1117_CR59","first-page":"644","volume":"17","author":"J Winegarden","year":"2016","unstructured":"Winegarden J, Carr DB, Bradshaw Y. Intravenous ketamine for rapid opioid dose reduction, reversal of opioid-induced neurotoxicity, and pain control in terminal care: case report and literature review. Pain Med. 2016;17:644\u20139.","journal-title":"Pain Med"},{"key":"1117_CR60","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/AJP.0b013e3181a68a85","volume":"25","author":"S Mercadante","year":"2009","unstructured":"Mercadante S, Villari P, Ferrera P, Arcuri E, David F. Opioid switching and burst ketamine to improve the opioid response in patients with movement-related pain due to bone metastases. Clin J Pain. 2009;25:648\u20139.","journal-title":"Clin J Pain"},{"key":"1117_CR61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.critrevonc.2015.12.011","volume":"99","author":"S Mercadante","year":"2016","unstructured":"Mercadante S, Bruera E. Opioid switching in cancer pain: from the beginning to nowadays. Crit Rev Oncol Hematol. 2016;99:241\u20138.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1117_CR62","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G","volume":"86","author":"S Mercadante","year":"1999","unstructured":"Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86:1856\u201366.","journal-title":"Cancer"},{"key":"1117_CR63","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1089\/jpm.2022.0266","volume":"25","author":"A Reddy","year":"2022","unstructured":"Reddy A, Sinclair C, Crawford GB, et al. Opioid rotation and conversion ratios used by palliative care professionals: an international survey. J Palliat Med. 2022;25:1557\u201362.","journal-title":"J Palliat Med."},{"key":"1117_CR64","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ejca.2011.11.039","volume":"48","author":"S Mercadante","year":"2012","unstructured":"Mercadante S. Stop and go strategy for opioid switching requires flexibility. Eur J Cancer. 2012;48:944\u20135.","journal-title":"Eur J Cancer"},{"key":"1117_CR65","first-page":"10","volume":"1","author":"S Mercadante","year":"2012","unstructured":"Mercadante S, Ferrera P, Arcuri E, Casuccio A. Opioid-induced hyperalgesia after rapid titration with intravenous morphine: switching and re-titration to intravenous methadone. Ann Palliat Med. 2012;1:10\u20133.","journal-title":"Ann Palliat Med"},{"key":"1117_CR66","doi-asserted-by":"publisher","first-page":"537","DOI":"10.21037\/apm.2020.03.05","volume":"9","author":"ML McPherson","year":"2020","unstructured":"McPherson ML. Why equianalgesic tables are only part of the answer to equianalgesia. Ann Palliat Med. 2020;9:537\u201341.","journal-title":"Ann Palliat Med"},{"key":"1117_CR67","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jpainsymman.2009.06.004","volume":"38","author":"PE Shaheen","year":"2009","unstructured":"Shaheen PE, Walsh D, Lasheen W, Davis MP, Lagman RL. Opioid equianalgesic tables: are they all equally dangerous? J Pain Symptom Manag. 2009;38:409\u201311.","journal-title":"J Pain Symptom Manag"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-023-01117-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T04:16:55Z","timestamp":1696306615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-023-01117-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,9]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1117"],"URL":"https:\/\/doi.org\/10.1007\/s11864-023-01117-9","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,9]]},"assertion":[{"value":"6 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors did not receive support from any organization for the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any\u00a0studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}